Compounds > n-acetylamrinone
Page last updated: 2024-12-08

n-acetylamrinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetylamrinone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID162980
SCHEMBL ID11450045
MeSH IDM0080805

Synonyms (8)

Synonym
n-acetylamrinone
62749-47-7
n-(2-oxo-5-pyridin-4-yl-1h-pyridin-3-yl)acetamide
acetamide, n-(1,6-dihydro-6-oxo(3,4'-bipyridin)-5-yl)-
n-(1,6-dihydro-5-oxo(3,4'-bipyridin)-5-yl)acetamide
SCHEMBL11450045
n-(6-hydroxy[3,4'-bipyridin]-5-yl)ethanimidic acid
DTXSID00978391

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The elimination half-life of amrinone was 10."( Pharmacokinetics of amrinone in neonates and infants.
Ahonen, J; Laitinen, P; Olkkola, KT; Peltola, K; Räsänen, J; Rautiainen, P, 2000)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's4 (50.00)18.2507
2000's2 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.29 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amrinone
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.		3.4880bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
olprinone
olprinone: RN refers to HCl; structure given in first source		2.0110bipyridines
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		1.9510
ConditionIndicatedRelationship StrengthStudiesTrials
Thrombopenia
[description not available]		02.420
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		02.420
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9910
Group A Strep Infection
[description not available]		01.9910
Streptococcal Infections
Infections with bacteria of the genus STREPTOCOCCUS.		01.9910
Abnormality, Heart
[description not available]		0210
Heart Defects, Congenital
Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.		0210